Basic Information
| LncRNA/CircRNA Name | HULC |
| Synonyms | NA |
| Region | GRCh38_6:8435568-9294133 |
| Ensemble | ENSG00000251164 |
| Refseq | NR_004855 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bone neoplasms |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot |
| Sample | cell lines (OUMS-27, HT1080, U20S, Saos-2, MG-63, XPTS-, hFOB) |
| Expression Pattern | up-regulated |
| Function Description | we found lncRNA HULC was over-expressed in all 6 bone neoplasm cell lines. lncRNA HULC has prognostic value in patients with bone neoplasms. LncRNA HULC can promote the tumorigenesis of bone neoplasms through increasing the proliferation, invasion, and migration abilities and the expression level of EMT-related factors. |
| Pubmed ID | 30120220 |
| Year | 2018 |
| Title | Long Non-Coding RNA HULC Promotes Progression of Bone Neoplasms. |
External Links
| Links for HULC | GenBank HGNC NONCODE |
| Links for bone neoplasms | OMIM COSMIC |